KRAS gene amplification and overexpression but not mutation associates with aggressive and metastatic endometrial cancer

British Journal of Cancer

Volumn 107, Issue 12, 2012, Pages 1997-2004

  Birkeland, E ^a,b   Wik, E ^a,b   Mjos, S ^a,b   Hoivik, E A ^a,b   Trovik, J ^a,b   Werner, H M J ^a,b   Kusonmano, K ^a,b,c   Petersen, K ^c   Raeder, M B ^a,b   Holst, F ^d   Oyan A M ^a,b   Kalland, K H ^a,b   Akslen, L A ^a,b   Simon, R ^d   Krakstad, C ^a,b   Salvesen, H B ^a,b  

^a HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF BERGEN   (Norway)

^c Uni Research AS   (Norway)

^d UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

amplification; endometrial cancer; KRAS; mutation; prognosis

Indexed keywords

ESTROGEN RECEPTOR ALPHA; K RAS PROTEIN; MESSENGER RNA; PROGESTERONE RECEPTOR;

ADULT; AGED; ANEUPLOIDY; ARTICLE; CANCER TISSUE; CARCINOGENESIS; CONTROLLED STUDY; COPY NUMBER VARIATION; DISEASE COURSE; ENDOMETRIOID CARCINOMA; ENDOMETRIUM CARCINOMA; FEMALE; GAIN OF FUNCTION MUTATION; GENE AMPLIFICATION; GENE EXPRESSION PROFILING; GENE OVEREXPRESSION; GENETIC ASSOCIATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; ONCOGENE K RAS; PRIORITY JOURNAL;

ADULT; AGED; ENDOMETRIAL NEOPLASMS; FEMALE; GENE AMPLIFICATION; GENE DOSAGE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, RAS; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHATIC METASTASIS; MIDDLE AGED; MUTATION; NEOPLASM GRADING; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHENOTYPE; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; SEQUENCE ANALYSIS, DNA; TISSUE ARRAY ANALYSIS; UP-REGULATION;

EID: 84870777479     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2012.477     Document Type: Article

References (40)

1. Cepero V, Sierra JR, Corso S, Ghiso E, Casorzo L, Perera T, Comoglio PM,Giordano S (2010) MET and KRAS gene amplification mediates acquiredresistance to MET tyrosine kinase inhibitors. Cancer Res 70(19):7580-7590
2. Chiang JM, Chou YH, Chou TB (1998) K-ras codon 12 mutation determinesthe polypoid growth of colorectral cancer. Cancer Res 58(15): 3289-3293
3. Dedes KJ, Wetterskog D, Ashworth A, Kaye SB, Reis-Filho JS (2011)Emerging therapeutic targets in endometrial cancer. Nat Rev Clin Oncol8(5): 261-271
4. Dobrzycka B, Terlikowski SJ, Mazurek A, Kowalczuk O, Niklinska W,Chyczewski L, Kulikowski M (2009) Mutations of the KRAS oncogene inendometrial hyperplasia and carcinoma. Folia Histochem Cytobiol 47(1):65-68
5. Engelsen IB, Stefansson I, Akslen LA, Salvesen HB (2006) Pathologicexpression of p53 or p16 in preoperative curettage specimensidentifies high-risk endometrial carcinomas. Am J Obstet Gynecol195(4): 979-986
6. Engelsen IB, Stefansson IM, Akslen LA, Salvesen HB (2008) GATA3expression in estrogen receptor alpha-negative endometrial carcinomasidentifies aggressive tumors with high proliferation and poor patientsurvival. Am J Obstet Gynecol 199(5): 543 e1-543 e7
7. Esteller M, Garcia A, Martinez-alones JM, Xercavins J, Reventos J (1997)The clinicopathological significance of K-RAS point mutation and geneamplification in endometrial cancer. Eur J Cancer 33(10): 1572-1577
8. FIGO IFoGaO (1989) Corpus cancer staging. Int J Gynecol Obstet 28:189-190
9. Fujimoto T, Nanjyo H, Fukuda J, Nakamura A, Mizunuma H, Yaegashi N,Sugiyama T, Kurachi H, Sato A, Tanaka T (2009) Endometrioid uterinecancer: histopathological risk factors of local and distant recurrence.Gynecol Oncol 112(2): 342-347
10. Fukuyama Y, Mitsudomi T, Sugio K, Ishida T, Akazawa K, Sugimachi K(1997) K-ras and p53 mutations are an independent unfavourableprognostic indicator in patients with non-small-cell lung cancer.Br J Cancer 75(8): 1125-1130
11. Gautschi O, Huegli B, Ziegler A, Gugger M, Heighway J, Ratschiller D, MackPC, Gumerlock PH, Kung HJ, Stahel RA, Gandara DR, Betticher DC(2007) Origin and prognostic value of circulating KRAS mutations inlung cancer patients. Cancer Lett 254(2): 265-273
12. Ito K, Watanabe K, Nasim S, Sasano H, Sato S, Yajima A, Silverberg SG,Garrett CT (1996) K-ras point mutations in endometrial carcinoma:effect on outcome is dependent on age of patient. Gynecol Oncol 63(2):238-246
13. Janku F, Wheler JJ, Westin SN, Moulder SL, Naing A, Tsimberidou AM, FuS, Falchook GS, Hong DS, Garrido-Laguna I, Luthra R, Lee JJ, Lu KH,Kurzrock R (2012) PI3K/AKT/mTOR inhibitors in patients with breastand gynecologic malignancies harboring PIK3CA mutations. J Clin Oncol30(8): 777-782
14. Jones MW, Kounelis S, Hsu C, Papadaki H, Bakker A, Swalsky PA,Finkelstein SD (1997) Prognostic value of p53 and K-ras-2 topographicgenotyping in endometrial carcinoma: a clinicopathologic and molecularcomparison. Int J Gynecol Pathol 16(4): 354-360
15. Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S,Torhorst J, Mihatsch MJ, Sauter G, Kallioniemi OP (1998) Tissuemicroarrays for high-throughput molecular profiling of tumor specimens.Nat Med 4(7): 844-847
16. Krakstad C, Trovik J, Wik E, Engelsen IB, Werner HM, Birkeland E, RaederMB, Oyan AM, Stefansson IM, Kalland KH, Akslen LA, Salvesen HB(2012) Loss of GPER identifies new targets for therapy among a subgroupof ERalpha-ositive endometrial cancer patients with poor outcome.Br J Cancer 106(10): 1682-1688
17. Lax SF, Pizer ES, Ronnett BM, Kurman RJ (1998) Clear cell carcinoma of theendometrium is characterized by a distinctive profile of p53, Ki-67,estrogen, and progesterone receptor expression. Hum Pathol 29(6): 551-558
18. Lievre A, Bachet JB, Le Corre D, Boige V, Landi B, Emile JF, Cote JF,Tomasic G, Penna C, Ducreux M, Rougier P, Penault-Llorca F, Laurent-uig P (2006) KRAS mutation status is predictive of response tocetuximab therapy in colorectal cancer. Cancer Res 66(8): 3992-3995
19. Ling J, Kang Y, Zhao R, Xia Q, Lee DF, Chang Z, Li J, Peng B, Fleming JB,Wang H, Liu J, Lemischka IR, Hung MC, Chiao PJ (2012) KrasG12DinducedIKK2/ beta/NF-kappaB activation by IL-1alpha and p62 feedforwardloops is required for development of pancreatic ductal adenocarcinoma.Cancer Cell 21(1): 105-120
20. McBryan J, Theissen SM, Byrne C, Hughes E, Cocchiglia S, Sande S,O'Hara J, Tibbitts P, Hill AD, Young LS (2012) Metastatic progressionwith resistance to aromatase inhibitors is driven by the steroid receptorcoactivator SRC-1. Cancer Res 72(2): 548-559
21. Mikuta JJ (1993) International Federation of Gynecology and Obstetricsstaging of endometrial cancer 1988. Cancer 71(4 Suppl): 1460-1463
22. Mizuuchi H, Nasim S, Kudo R, Silverberg SG, Greenhouse S, Garrett CT(1992) Clinical implications of K-ras mutations in malignant epithelialtumors of the endometrium. Cancer Res 52(10): 2777-2781
23. Mutter GL, Wada H, Faquin WC, Enomoto T (1999) K-ras mutationsappear in the premalignant phase of both microsatellite stable andunstable endometrial carcinogenesis. Mol Pathol 52(5): 257-262
24. Oza AM, Eisenhauer EA, Elit L, Cutz JC, Sakurada A, Tsao MS, Hoskins PJ,Biagi J, Ghatage P, Mazurka J, Provencher D, Dore N, Dancey J, Fyles A(2008) Phase II study of erlotinib in recurrent or metastatic endometrialcancer: NCIC IND-148. J Clin Oncol 26(26): 4319-4325
25. Pao W, Wang TY, Riely GJ, Miller VA, Pan Q, Ladanyi M, Zakowski MF,Heelan RT, Kris MG, Varmus HE (2005) KRAS mutations and primaryresistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med2(1): e17
26. Pappa KI, Choleza M, Markaki S, Giannikaki E, Kyroudi A, Vlachos G,Voulgaris Z, Anagnou NP (2006) Consistent absence of BRAF mutationsin cervical and endometrial cancer despite KRAS mutation status.Gynecol Oncol 100(3): 596-600
27. Pylayeva-Gupta Y, Grabocka E, Bar-Sagi D (2011) RAS oncogenes: weavinga tumorigenic web. Nat Rev Cancer 11(11): 761-774
28. Rachagani S, Senapati S, Chakraborty S, Ponnusamy MP, Kumar S, SmithLM, Jain M, Batra SK (2011) Activated Kras(G12D) is associated withinvasion and metastasis of pancreatic cancer cells through inhibition ofE-cadherin. Br J Cancer 104(6): 1038-1048
29. Rosell R, Li S, Skacel Z, Mate JL, Maestre J, Canela M, Tolosa E, ArmengolP, Barnadas A, Ariza A (1993) Prognostic impact of mutated K-ras genein surgically resected non-small cell lung cancer patients. Oncogene 8(9):2407-2412
30. Salvesen HB, Carter SL, Mannelqvist M, Dutt A, Getz G, Stefansson IM,Raeder MB, Sos ML, Engelsen IB, Trovik J, Wik E, Greulich H, Bo TH,Jonassen I, Thomas RK, Zander T, Garraway LA, Oyan AM, Sellers WR,Kalland KH, Meyerson M, Akslen LA, Beroukhim R (2009) Integrated genomic profiling of endometrial carcinoma associates aggressivetumors with indicators of PI3 kinase activation. Proc Natl Acad SciUSA 106(12): 4834-4839
31. Salvesen HB, Das S, Akslen LA (2000) Loss of nuclear p16 proteinexpression is not associated with promoter methylation but defines asubgroup of aggressive endometrial carcinomas with poor prognosis.Clin Cancer Res 6(1): 153-159
32. Sasaki H, Hikosaka Y, Kawano O, Moriyama S, Yano M, Fujii Y (2011)Evaluation of Kras gene mutation and copy number gain in non-smallcell lung cancer. J Thorac Oncol 6(1): 15-20
33. Semczuk A, Berbec H, Kostuch M, Cybulski M, Wojcierowski J, BaranowskiW (1998) K-ras gene point mutations in human endometrial carcinomas:correlation with clinicopathological features and patients' outcome.J Cancer Res Clin Oncol 124(12): 695-700
34. Sernbo S, Gustavsson E, Brennan DJ, Gallagher WM, Rexhepaj E, RydnertF, Jirstrom K, Borrebaeck CA, Ek S (2011) The tumour suppressor SOX11is associated with improved survival among high grade epithelial ovariancancers and is regulated by reversible promoter methylation. BMCCancer 11: 405
35. Span M, Moerkerk PT, De Goeij AF, Arends JW (1996) A detailed analysisof K-ras point mutations in relation to tumor progression and survival incolorectal cancer patients. Int J Cancer 69(3): 241-245
36. Trovik J, Wik E, Stefansson IM, Marcickiewicz J, Tingulstad S, Staff AC,Njolstad TS, Vandenput I, Amant F, Akslen LA, Salvesen HB (2011)Stathmin overexpression identifies high-risk patients and lymphnode metastasis in endometrial cancer. Clin Cancer Res 17(10):3368-3377
37. Wagner PL, Perner S, Rickman DS, LaFargue CJ, Kitabayashi N,Johnstone SF, Weir BA, Meyerson M, Altorki NK, Rubin MA (2009) Insitu evidence of KRAS amplification and association with increasedp21 levels in non-small cell lung carcinoma. Am J Clin Pathol 132(4):500-505
38. Wagner PL, Stiedl AC, Wilbertz T, Petersen K, Scheble V, Menon R, ReischlM, Mikut R, Rubin MA, Fend F, Moch H, Soltermann A, Weder W,Altorki NK, Perner S (2011) Frequency and clinicopathologic correlatesof KRAS amplification in non-small cell lung carcinoma. Lung Cancer74(1): 118-123
39. Zeng M, Kikuchi H, Pino MS, Chung DC (2010) Hypoxia activates the K-rasproto-oncogene to stimulate angiogenesis and inhibit apoptosis in coloncancer cells. PLoS One 5(6): e10966
40. Zhang JS, Koenig A, Harrison A, Ugolkov AV, Fernandez-Zapico ME,Couch FJ, Billadeau DD (2011) Mutant K-Ras increases GSK-3beta geneexpression via an ETS-300 transcriptional complex in pancreaticcancer. Oncogene 30(34): 3705-3715